Survival rate

Celebrities Unite for St. Jude Children’s Research Hospital Annual #ThisShirtSavesLives Movement

Retrieved on: 
Monday, December 11, 2023
Fashion, Influencer, Retail, Other Philanthropy, Research, Children, TV and Radio, Oncology, Music, Consumer, Fund Raising, Hospitals, Foundation, Philanthropy, Science, Social Media, Entertainment, Health, Communications, CeCe Winans, NCI-designated Cancer Center, Travel, National Cancer Institute, The Bobby Bones Show, The Morning Show, Love, Food, GALE, National Cancer Research Institute, Multimedia, Photograph, Partner, Survival rate, Social media, Child, IHeartMedia, Cancer, Housing, Lynch, Sensation, Jelly roll, Mya, Hospital, Nightclub, Hope, Jude the Apostle

This annual series of nationwide events is part of the Music Gives to St. Jude Kids campaign that connects music lovers to the mission of St. Jude.

Key Points: 
  • This annual series of nationwide events is part of the Music Gives to St. Jude Kids campaign that connects music lovers to the mission of St. Jude.
  • St. Jude Children’s Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection

Retrieved on: 
Tuesday, December 5, 2023
Research, Medical Devices, Surgery, Genetics, Clinical Trials, Biotechnology, Managed Care, Health, Science, Oncology, Pancreatic cancer, Medical director, Disease, Risk, Patient, UC San Diego Health, Biology, Pancreas, PDAC, Survival rate, Master of Science, Exosome, Moores Cancer Center, University of Florida Health, Seminal vesicles, University, Diagnosis, Cancer, Pancreatitis, Doctor of Philosophy, Dana–Farber Cancer Institute, Pharmaceutical industry, MedStar Georgetown University Hospital, MD

Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
  • Known as a “silent killer,” approximately 80% of pancreatic cancer patients discover the disease in late stages when it has already spread and cannot be surgically removed.
  • “Currently, there is no standard early detection test for pancreatic cancer, resulting in an unmet need for innovative solutions to help solve this challenging disease,” said Harmeet Dhani, MD, MSc, Medical Director at Biological Dynamics and Principal Study Investigator.
  • “Collaborating with these cutting-edge institutions expands our work with some of the top cancer researchers in the world.

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

Retrieved on: 
Monday, December 4, 2023
Oncology, Health, Health Technology, Clinical Trials, Research, Science, Biotechnology, SCCHN, Indometacin, Neck, Safety, NYSE, Radiation, Neoadjuvant therapy, Head, Risk, Patient, Zinc, FRCR, Lymph, Cancer Research UK, Survival rate, NHS, NIHR, NHS Wales, National Health Service, MD, Death, Survival, Cyclophosphamide, Recurrence, Social work, Pharmaceutical industry, Nursing, Health care

NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.

Key Points: 
  • NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
  • This published report informs UK doctors, patients, and other interested parties that NICE has started the review of Multikine and is soliciting public comment.
  • The NICE briefing includes the following statements:
    “The current standard of care for locally advanced SCCHN is an aggressive combined modality therapy.
  • According to Cancer Research UK , an average of 12,400 cases of head and neck cancer are diagnosed each year in the UK.

Emma Roberts, Santa J Claus, and Influencers Unite for Giving Tuesday to Support St. Jude Children’s Research Hospital

Retrieved on: 
Tuesday, November 21, 2023
Health, Hospitals, NCI-designated Cancer Center, Hope, National Cancer Institute, Food, Love, Tune, National Cancer Institute (Egypt), Multimedia, ALSAC, Williams-Sonoma, Inc., Survival rate, Movement, Estate (law), HSN, Child, Cancer, Housing, Brooks Brothers, Travel, Hospital, Nightclub, Casino, Jude the Apostle

View the full release here: https://www.businesswire.com/news/home/20231121621942/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231121621942/en/
    Donations from Giving Tuesday activations help kids like St. Jude patient Eri’Elle receive the treatment they need.
  • Tune in to the TikTok Live Give-a-Thon , a six-hour event with co-host Santa J Claus , an avid supporter of St. Jude who spreads cheer throughout the world.
  • St. Jude Children’s Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

St. Jude Thanks and Giving campaign celebrates 20th anniversary

Retrieved on: 
Monday, November 13, 2023
Children, Hospitals, Philanthropy, Health, Fund Raising, Consumer, General Health, Foundation, Oncology, Well, Holiday, Sale, Presto, Best Buy, NCI-designated Cancer Center, Sterling Jewelers, Research, Hope, Zale Corporation, National Cancer Institute, AutoZone, Love, Food, Restaurant, National Cancer Survivors Day, Multimedia, Patient, ALSAC, Williams-Sonoma, Inc., Survival rate, Donation, Estate (law), Child, Cancer, Housing, Good, HomeGoods, Williams Sonoma, Kia, Travel, Hospital, Grocery store, Nursing, Dine, Jude the Apostle, American Freight, Chili

The St. Jude Thanks and Giving ® campaign is celebrating 20 years of bringing together celebrities, businesses and consumers to support St. Jude Children’s Research Hospital ®.

Key Points: 
  • The St. Jude Thanks and Giving ® campaign is celebrating 20 years of bringing together celebrities, businesses and consumers to support St. Jude Children’s Research Hospital ®.
  • Some ways to support the campaign include:
    Best Buy customers can donate to St. Jude via online, in-store and mobile ordering.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA

Retrieved on: 
Monday, December 18, 2023
Huntington's disease, Glioma, Safety, ATN, Food, ODD, Glioblastoma, GBM, Clinical trial, Mortality, Patient, Multimedia, Radiation, FDA, Alzheimer's disease, Survival rate, Stroke, Health, Salvage therapy, Recurrence, Survival, Quality of life, AAV, Pharmaceutical industry, ALS

PHILADELPHIA, Dec. 18, 2023 /PRNewswire/ -- On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being developed by NeuExcell Therapeutics Inc. ("NeuExcell"), for the treatment of malignant glioma.

Key Points: 
  • PHILADELPHIA, Dec. 18, 2023 /PRNewswire/ -- On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being developed by NeuExcell Therapeutics Inc. ("NeuExcell"), for the treatment of malignant glioma.
  • This is the world's first AAV gene therapy product for malignant glioma to receive FDA ODD designation.
  • Malignant gliomas are the most common primary malignant brain tumors in adults, about 60% of which are glioblastoma (GBM).
  • Recurrence is virtually inevitable for malignant glioma and there is no clear standard salvage therapy.

Enzyme Innovation's New Study on the Stability & Effect of Bacillus coagulans LBSC on the Sensory Attributes of Food Products was Published in the Global Journal of Microbiology and Biotechnology

Retrieved on: 
Tuesday, December 5, 2023
Research, Food, Bacillus coagulans, Chocolate, Dave's Picks Volume 11, Survival rate, LBSC, Tortilla chip, Doc Comparato, Taste, SEB, Dietary supplement, Biotechnology, Microbiology

CHINO, Calif., Dec. 5, 2023 /PRNewswire/ -- A study published in the Global Journal of Microbiology and Biotechnology finds adding the probiotic, Bacillus coagulans LBSC (SEB LBSC), to food products offers promising health benefits while maintaining the food's appearance, aroma, taste and texture.

Key Points: 
  • CHINO, Calif., Dec. 5, 2023 /PRNewswire/ -- A study published in the Global Journal of Microbiology and Biotechnology finds adding the probiotic, Bacillus coagulans LBSC (SEB LBSC), to food products offers promising health benefits while maintaining the food's appearance, aroma, taste and texture.
  • "The findings of this research point to a significant opportunity for food manufacturers," said Vic Rathi, President of Enzyme Innovation.
  • Known for being heat-stable and spore-forming, Bacillus coagulans LBSC demonstrated robust stability when added to the tested food products, with a survival rate ranging from 42 to 98% (depending on the food).
  • Bacillus coagulans LBSC was added using conventional processes without the need for specialized equipment, making it a cost-effective option for various food items and promoting widespread accessibility.

New Report Shows Significant Lung Cancer Survival Rate Gains, Lingering Disparities and Urgent Need for Increased Screening

Retrieved on: 
Tuesday, November 14, 2023
Lung, American Lung Association, Health, Medicaid, Disease, Diagnosis, Canadian Lung Association, Patient, Survival rate, Medicaid coverage gap, COVID-19, Lung cancer, Survival, Congress, Face, Uranium mining, Medical imaging

CHICAGO, Nov. 14, 2023 /PRNewswire/ -- Lung cancer survival rates are improving for everyone, including people of color, according to the American Lung Association's 2023 "State of Lung Cancer" report, released today. The five-year lung cancer survival rate for people of color has increased by 17% in the last two years, helping close the health disparity gap.

Key Points: 
  • American Lung Association's 'State of Lung Cancer' report reveals improvement in survival rate for people of color, examines toll of lung cancer state-by-state
    CHICAGO, Nov. 14, 2023 /PRNewswire/ -- Lung cancer survival rates are improving for everyone, including people of color, according to the American Lung Association's 2023 "State of Lung Cancer" report , released today.
  • We are encouraged by the work being done to eliminate lung cancer stigma, increase lung cancer screening and improve lung cancer treatment," said Harold Wimmer, President and CEO of the American Lung Association.
  • Lung cancer screening with annual low-dose CT scans for those at high risk can reduce the lung cancer death rate by up to 20%.
  • The 2023 "State of Lung Cancer" report highlights that states must do more to reduce the burden of lung cancer and encourages everyone to help end lung cancer.

Red Roof® Partners with St. Jude Children's Research Hospital® this Holiday Season to Help Defeat Childhood Cancer

Retrieved on: 
Monday, November 13, 2023
Research, Senior, Organization, Food, Red, Insurance, American Cancer Society, ALSAC, Survival rate, Child, Thurgood Marshall College, Cancer, Housing, Room in Your Heart, Life, Travel, United Way, Nursing, Jude the Apostle

St. Jude is leading the way the world understands, treats, and defeats childhood cancer and other life-threatening diseases.

Key Points: 
  • St. Jude is leading the way the world understands, treats, and defeats childhood cancer and other life-threatening diseases.
  • * Guests may book directly using VP Code 628790 at redroof.com or on the app, by calling 800.RED.ROOF, or any property, to support St. Jude.
  • In recognition of the significant contributions Red Roof has made to St. Jude over the years, Red Roof was selected to receive the 2023 St. Jude Emerging Partner of the Year Award, presented by ALSAC and St. Jude Children's Research Hospital.
  • "Since 2021, the support of Red Roof has helped St. Jude Children's Research Hospital continue to accelerate research and treatment for childhood cancer and other life-threatening diseases," said Lyles Eddins, Senior Vice President of Relational Advancement for ALSAC , the fundraising and awareness organization for St. Jude Children's Research Hospital.

Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001

Retrieved on: 
Friday, November 10, 2023
Priority review, Korean Ministry of Culture, Safety, MFDS, Cancer, GBM, Clinical trial, Mortality, Fast track (FDA), Patient, Reverse transcriptase, Central nervous system, FDA, Survival rate, Sympathetic nervous system, Messenger, Therapy, Accelerated approval (FDA), RNA, Pharmaceutical industry, Medical device, Food, Glioblastoma

Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs, thus enabling drugs to reach patients sooner.

Key Points: 
  • Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs, thus enabling drugs to reach patients sooner.
  • If relevant criteria are met, the drug with Fast Track Designation may also be eligible for Accelerated Approval and Priority Review.
  • GBM is known as the most malignant tumor in Central Nervous system with high mortality rate but lacks effective therapies.
  • "We are proud to receive Fast Track Designation from the FDA," said Dr. Seong-Wook Lee, Chief Executive Officer of Rznomics.